NCT06972056
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 36 → 39 locations
- Minor Study sites: 36 to 37
- Notable Eligibility criteria expanded, about 28 words
- Secondary endpoints: details revised at 2 of 4 entries
- Site contacts updated at 5 of 36 sites
- Minor Study sites: 35 to 36v14
- Minor Site contacts updated at 3 of 35 sitesv13
- Minor Study sites revised (35)v12
- Minor Trial sites expanded: 23 → 35 locationsv11
- Minor Trial sites expanded: 18 → 23 locationsv10
- Minor Study sites: 17 to 18v9
- Minor Study sites: 9 to 17v8
- Minor Study sites: 7 to 9v7
- Minor Start date changed from estimate of Jul 2025 to Jul 9, 2025
- Site details revised at 1 of 7 sites
- Minor Study sites revised (7)v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 5 to 7
- Minor Site contacts updated at 1 of 5 sitesv3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)
Timeframe: Weeks 9-12 post-randomization compared to the 4 weeks prior to randomization
Secondary (4)
Migraine Specific Quality-of-Life - Role Function-Restrictive
Treatment Responder (propranolol vs. topiramate)
Headache Impact Test-6 (HIT-6)
Medication-Related Adverse Events
Arms and interventions
AtogepantActive comparator
Participants who are randomized to this arm will take up to 60mg daily for 12 weeks.
PropranololActive comparator
Participants randomized to this arm will take up to 160 mg daily for 12 weeks.
TopiramateActive comparator
Participants randomized to this arm will take up to 100 mg daily for 12 weeks .
Drugs: Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg
Sites
39 sites in 1 country